← Back to headlines
ImmunityBio Acquires U.S. Rights to Tokyo Strain of BCG
ImmunityBio has announced its acquisition of the U.S. rights to the Tokyo strain of Bacillus Calmette-Guérin (BCG), a vaccine primarily used against tuberculosis and also for bladder cancer treatment.
16 May, 18:11 — 16 May, 18:11
Sources
Showing 1 of 1 sources
Related Stories
Heavy Rains and Thunderstorms Expected in Zambales After Heatwave
just now
Canadian Passenger from MV Hondius Confirmed Positive for Hantavirus
15m ago
Switzerland Plans Ban on Unhealthy Food Advertising to Combat Childhood Obesity
22m ago
Zurich University Hospital Tightens Rules Following Maisano Heart Surgery Scandal
31m ago